PE20081457A1 - Asenapina amorfa, procesos para prepararlas y su uso para tratar trastornos del sistema nervioso central - Google Patents

Asenapina amorfa, procesos para prepararlas y su uso para tratar trastornos del sistema nervioso central

Info

Publication number
PE20081457A1
PE20081457A1 PE2007001353A PE2007001353A PE20081457A1 PE 20081457 A1 PE20081457 A1 PE 20081457A1 PE 2007001353 A PE2007001353 A PE 2007001353A PE 2007001353 A PE2007001353 A PE 2007001353A PE 20081457 A1 PE20081457 A1 PE 20081457A1
Authority
PE
Peru
Prior art keywords
compound
asenapin
amorpha
prepare
processes
Prior art date
Application number
PE2007001353A
Other languages
English (en)
Inventor
Melissa Jean Casteel
Wilhelmus Petrus Hubertus Maria Wildt
Original Assignee
Organon Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Organon Nv filed Critical Organon Nv
Publication of PE20081457A1 publication Critical patent/PE20081457A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

SE REFIERE A ASEPINA AMORFA O TAMBIEN DENOMINADA TRANS-5-CLORO-2-METIL-2,3,3a,12b-TETRAHIDRO-1H-DIBENZ[2,3:6,7]OXEPINO[4,5-c]PIRROL, DONDE ESTE COMPUESTO ES AL MENOS 50% AMORFO, EN BASE AL PESO TOTAL DEL COMPUESTO, EL CUAL ES CARACTERIZADO POR PRESENTAR UN ESPECTRO DE RMN DE ESTADO SOLIDO DE C13 QUE TIENE DESPLAZAMIENTOS QUIMICOS EN PPM DE 169,9; 136,4; 129,5 Y 42,6; UN PATRON DE DIFRACCION DE RAYOS X PRESENTANDO UN PICO AMPLIO UNICO ENTRE 15º Y 30º; Y UNA TEMPERATURA DE INICIO DE TRANCISION VITREA DE 38ºC A 53ºC. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA SOLIDA PREFERENTEMENTE DE ADMINISTRACION SUBLINGUAL O BUCAL; Y A UN PROCEDIMIENTO DE PREPARACION A PARTIR DE UN PRECURSOR QUE COMPRENDE UNA SAL DE ACIDO MALEICO DEL COMPUESTO. SIENDO UTILES EN EL TRATAMIENTO DE TRASTORNOS DEL SNC INCLUYENDO ESQUIZOFRENIA Y TRASTORNO BIPOLAR
PE2007001353A 2006-10-06 2007-10-05 Asenapina amorfa, procesos para prepararlas y su uso para tratar trastornos del sistema nervioso central PE20081457A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US82853506P 2006-10-06 2006-10-06

Publications (1)

Publication Number Publication Date
PE20081457A1 true PE20081457A1 (es) 2008-10-18

Family

ID=39019120

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007001353A PE20081457A1 (es) 2006-10-06 2007-10-05 Asenapina amorfa, procesos para prepararlas y su uso para tratar trastornos del sistema nervioso central

Country Status (8)

Country Link
US (1) US20080090892A1 (es)
EP (1) EP2078024A1 (es)
AR (1) AR063158A1 (es)
CA (1) CA2667668A1 (es)
CL (1) CL2007002891A1 (es)
PE (1) PE20081457A1 (es)
TW (1) TW200831514A (es)
WO (1) WO2008040816A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010127674A1 (en) * 2009-05-06 2010-11-11 Sunin K/S Transdermal compositions of asenapine for the treatment of psychiatric disorders
CA2802990A1 (en) * 2010-06-18 2011-12-22 Dr. Reddy's Laboratories Ltd. Asenapine maleate
WO2012066565A2 (en) 2010-11-16 2012-05-24 Cadila Healthcare Limited Asenapine maleate amorphous and crystalline form and process for preparation thereof
EP2468750A1 (en) 2010-12-13 2012-06-27 Chemo Ibérica, S.A. Polymorphic forms of asenapine maleate and processes for their preparation
JP5638151B2 (ja) * 2010-12-23 2014-12-10 パーデュー、ファーマ、リミテッド、パートナーシップ 不正加工抵抗性の（ｔａｍｐｅｒｒｅｓｉｓｔａｎｔ）固形経口剤形
WO2012114325A1 (en) * 2011-02-23 2012-08-30 Mapi Pharma Limited Polymorphs of asenapine maleate
ITMI20110734A1 (it) 2011-05-02 2012-11-03 Olon Spa Sali cristallini di asenapina
WO2013024492A2 (en) 2011-07-01 2013-02-21 Megafine Pharma (P) Ltd. A process for the preparation of asenapine and novel salts thereof
WO2013114400A2 (en) * 2012-01-20 2013-08-08 Rubicon Research Private Limited Compressed pharmaceutical compositions of atypical antipsychotics
ITMI20121810A1 (it) 2012-10-24 2014-04-25 Chemo Iberica Sa Poliformi di maleato di asenapina e processo per la loro preparazione
US9597291B2 (en) * 2012-12-11 2017-03-21 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Orally disintegrating tablet containing asenapine
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
CN110087640A (zh) 2016-12-20 2019-08-02 罗曼治疗系统股份公司 包含阿塞那平的透皮治疗系统
KR102614709B1 (ko) 2016-12-20 2023-12-18 에르테에스 로만 테라피-시스테메 아게 아세나핀 및 폴리실록산 또는 폴리이소부틸렌을 함유하는 경피흡수 치료 시스템
US11033512B2 (en) 2017-06-26 2021-06-15 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine and silicone acrylic hybrid polymer
KR20210022656A (ko) 2018-06-20 2021-03-03 에르테에스 로만 테라피-시스테메 아게 아세나핀을 함유하는 경피 치료 시스템
CN110123793A (zh) * 2019-06-03 2019-08-16 深圳市泛谷药业股份有限公司 一种阿塞那平或其盐的贴剂及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7605526A (nl) * 1976-05-24 1977-11-28 Akzo Nv Nieuwe tetracyclische derivaten.
CN1309370C (zh) * 2002-02-01 2007-04-11 辉瑞产品公司 使用改进的喷雾干燥设备制备均匀喷雾干燥的固体非晶形药物分散体的方法
KR20070084123A (ko) * 2004-10-15 2007-08-24 엔.브이.오가논 양극성 장애 및 관련 증상의 치료
US20060258679A1 (en) * 2005-02-11 2006-11-16 Alex Mainfeld Process of preparing ziprasidone mesylate
SI1710245T1 (sl) * 2005-04-07 2007-12-31 Organon Nv Kristalna oblika asenapin maleata
US7872147B2 (en) * 2005-04-07 2011-01-18 N. V. Organon Intermediate compounds for the preparation of trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenz[2,3:6,7]oxepino[4,5-c]pyrrole

Also Published As

Publication number Publication date
TW200831514A (en) 2008-08-01
EP2078024A1 (en) 2009-07-15
AR063158A1 (es) 2008-12-30
US20080090892A1 (en) 2008-04-17
CA2667668A1 (en) 2008-04-10
WO2008040816A1 (en) 2008-04-10
CL2007002891A1 (es) 2008-04-18

Similar Documents

Publication Publication Date Title
PE20081457A1 (es) Asenapina amorfa, procesos para prepararlas y su uso para tratar trastornos del sistema nervioso central
NO20091328L (no) Pyrido[4,3-D]pyrimidin-4(3H)on-derivater som kalsiumreceptorantagonister
NO981858D0 (no) Fenyletanolamin-forbindelser anvendelige som <beta>3 agonist, fremgangsmÕte for fremstilling av disse og mellomprodukter i fremstilling av dem
MX2013014470A (es) Compuestos de pirazolo[3,4-d]pirimidina y su uso como inhibidores pde2 y/o inhibidores cyp3a4.
AR045134A1 (es) Compuesto de 1h - imidazo [4,5-c] piridin-ilo, composicion farmaceutica que lo comprende, proceso para prepararla, su uso para preparar dicha composicion farmaceutica, combinacion farmaceutica, uso de la combinacion farmaceutica para la preparacion de un medicamento, procedimientos para preparar dic
EA201390971A1 (ru) ИМИДАЗО[5,1-f][1,2,4]ТРИАЗИНЫ ДЛЯ ЛЕЧЕНИЯ НЕВРОЛОГИЧЕСКИХ РАССТРОЙСТВ
NO20063693L (no) Forbindelse og metode for anvendelse
MA33768B1 (fr) Triazolopyridines
ATE484504T1 (de) Imidazo ä1,2-aüpyridin-2-carboxamid-derivate, herstellungsverfahren und ihre verwendung für therapeutika
HK1112238A1 (en) Substituted benzo(d)isoxazol-3-yl amine compounds as analgesics
AR063979A1 (es) Antagonistas de receptor de orexina de diazepam sustituidos
UY28578A1 (es) Derivados de amida
HK1139858A1 (en) Combination therapy of substituted oxazolidinones
NO20090755L (no) Amino-imidazoloner og deres anvendelse som et medikament for behandling av kognitiv svekkelse, Alzheimers sykdom, neurodegenerering og demens
UY27503A1 (es) Nuevos derivados de piperazina
UY29212A1 (es) Azabenzoxazoles para el tratamiento de trastornos del snc
CY1109808T1 (el) Αρυλινδενο-πυριδινες και αρυλινδενο-πυριμιδινες και η χρηση τους ως ανταγωνιστων των υποδοχεων αδενοσινης α2α
SG171681A1 (en) Crystalline forms and processes for the preparation of phenyl-pyrazoles useful as modulators of the 5-ht2a serotonin receptor
NO20083708L (no) 4-Fenyl-tiazol-5-karboksylsyre og 4-fenyl-tiazol-5-karboksylmider som PLK1-inhibitorer
BRPI0411936A (pt) composto, processo para a sua preparação, composição farmacêutica que comprende o mesmo, utilização de um composto, métodos para o tratamento e profilaxia de distúrbios do sistema nervoso central, alimentares e obesidade
ECSP088257A (es) Derivados de amida
NO20092149L (no) Spiro-piperidinderivater
BRPI0808828A8 (pt) Compostos de dibenzo[b,f][1,4]oxazapina
ITMI20062102A1 (it) Nuovui sali di 3-benzil-2-metil-2,3,3a,4,5,6,7,7a-ottaidrobenzo-d-isossazol-4-one
ES2441996T3 (es) Procedimiento para la preparación de 4a,5,9,10,11,12,-hexahidro-6H-benzofuro[3a,3,2-ef][2]benzazepina altamente pura asi como sus derivados

Legal Events

Date Code Title Description
FD Application declared void or lapsed